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Generation of light-producing 
somatic-transgenic mice using 
adeno-associated virus vectors
Rajvinder Karda  1, Ahad A. Rahim2, Andrew M. S. Wong3, natalie Suff1, Juan Antinao Diaz  1, 
Dany p. perocheau1, Maha tijani1, Joanne ng1, Julien Baruteau1, nuria palomar Martin4, 
Michael Hughes2, Juliette M. K. M. Delhove  5, John R. counsell  6,7, Jonathan D. cooper3,8, 
els Henckaerts4,9, tristan R. Mckay10, Suzanne M. K. Buckley1* & Simon n. Waddington  1,11
We have previously designed a library of lentiviral vectors to generate somatic-transgenic rodents 
to monitor signalling pathways in diseased organs using whole-body bioluminescence imaging, in 
conscious, freely moving rodents. We have now expanded this technology to adeno-associated viral 
vectors. We first explored bio-distribution by assessing GFP expression after neonatal intravenous 
delivery of AAV8. We observed widespread gene expression in, central and peripheral nervous 
system, liver, kidney and skeletal muscle. next, we selected a constitutive SffV promoter and nfκB 
binding sequence for bioluminescence and biosensor evaluation. An intravenous injection of AAV8 
containing firefly luciferase and eGFP under transcriptional control of either element resulted in strong 
and persistent widespread luciferase expression. A single dose of LPS-induced a 10-fold increase in 
luciferase expression in AAV8-NFκB mice and immunohistochemistry revealed Gfp expression in cells 
of astrocytic and neuronal morphology. Importantly, whole-body bioluminescence persisted up to 240 
days. We have validated a novel biosensor technology in an AAV system by using an nfκB response 
element and revealed its potential to monitor signalling pathway in a non-invasive manner in a model 
of LPS-induced inflammation. This technology complements existing germline-transgenic models and 
may be applicable to other rodent disease models.
Germline light-producing transgenic mice where luciferase expression is controlled by an endogenous promoter, 
a surrogate promoter or by a minimal promoter downstream of tandem, synthetic, transcription factor binding 
elements, are used to provide an in vivo readout of physiological and pathological processes1,2. One of the advan-
tages of this technology is that every cell will contain a copy of the luciferase transgene and therefore provide a 
whole-body transgene expression profile under the control of a specific promoter of choice. However, producing 
germline transgenics requires frequent backcrossing and therefore becomes a time-consuming and costly process, 
using many rodents.
We have previously developed a novel technology which allows the generation of light-producing somatic 
transgenic rodents, using lentiviral vectors as a proof-of-concept system3 and have validated this technology both 
in vitro4,5 and in vivo1,6. We have also demonstrated that signalling pathways in diseased organs can be moni-
tored specifically, continually and in a non-invasive manner1,2. Exploiting the immune tolerance of neonatal mice 
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towards transgenic proteins7, we were able to achieve organ-specific transduction by a single neonatal adminis-
tration of the biosensor.
To achieve a better spread of delivery and target additional tissues, we explored adeno-associated viral (AAV) 
vectors to deliver the biosensor construct. Previous work has shown that AAV8 can achieve widespread transgene 
expression and cross the blood brain barrier (BBB) after an intravenous administration in adult rodents, targeting 
the brain, heart, liver and skeletal muscles8. Neonatal intraperitoneal administration of an AAV8 vector resulted 
in expression in pancreas9, kidney10 and spinal cord11.
In this study, we have shown extensive, systemic gene expression after a single neonatal intravenous admin-
istration of AAV8-CMV-eGFP to neonatal mice. We have generated AAV8 biosensors carrying either an NFκB 
response element or a constitutive SFFV promoter driving luciferase. Here for the first time we report the gener-
ation of light-emitting somatic transgenic rodents with a wider spread of transgene expression, following a single 
neonatal intravenous or intracranial administration of AAV8 biosensors. We validated the biosensing technology 
by administering LPS to model systemic inflammation and showed a significant increase in light emission. This 
technology will allow for expedited investigations regarding signalling pathways activated in disease processes 
and complement existing germline transgenic light-producing technology by maximising the use, and reducing 
the numbers of animals used in biomedical research.
Results
Neonatal intravenous administration of AAV8-CMV-GFP vector. We sought to determine the 
bio-distribution of GFP expression following neonatal (Post-neonatal day 1, P1) intravenous administration of 
AAV8-CMV-eGFP. On the day of birth, mice received 40μl of vector (1 × 1013 vector genomes/ml) via the super-
ficial temporal vein. One month later, mice were harvested and GFP expression was analysed, using a DFC420 
microscope.
Figure 1. Systemic distribution of GFP after a single neonatal intravenous administration of AAV8-CMV-GFP. 
New-born mice received an intravenous administration of AAV8-CMV-GFP vector (n = 3). At 1 month of age 
the mice were harvested and the ex vivo analysis of GFP expression revealed widespread systemic distribution. 
(A) Strong GFP expression was observed within the heart (B), liver (C), kidney (D), muscle (E), eye ball (F), 
brain (G) and the myenteric plexus. (H) Scale bar = 1.80 µm for A. Scale bar = 2.5 µm for B, D, E, F and G. Scale 
bar = 3 µm for C and H.
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Prior to gross dissection and further fixation, skin was removed and mice were viewed under a stereoscopic 
fluorescence microscope. Strong, extensive and widespread GFP expression was observed throughout the 
body, although the highest levels of expression were most noticeable in the musculature (Fig. 1). Strong trans-
duction was observed within the heart (B), liver (C), kidney (D), skeletal muscle (E), eye (F), brain (G), and 
myenteric plexus (H). At higher magnification, we observed a majority of GFP positive hepatocyte cells in the 
liver (Supplementary Fig. 1).
In order to assess the expression profile in the CNS, the brains from injected and non-injected control mice 
were sectioned and immunohistochemistry was conducted for GFP expression. This revealed extensive and wide-
spread GFP expression (Supplementary Fig. 2). Further examination under higher magnification of discrete areas 
of the brain including the primary motor cortex, the somatosensory barrel field (S1BF), piriform cortex, dentate 
gyrus, cerebellum, and the gigantocellular nucleus revealed transduction of cells with both neuronal and glial 
morphology (Supplementary Fig. 2).
Further to this we investigated whether AAV vector or GFP transgene expression triggers an inflammatory 
response after neonatal intracranial injections. Microglial activation was examined in all brains collected at 
35 days of development and compared to brain tissue from Ppt1−/− (palmitoyl protein thioesterase 1) mice in 
which profound microglial activation occurs12, and therefore serve as a positive control for microglial markers. 
Extensive microglial engorgement and activation was observed in the Ppt1−/− mice, and no noticeable activation 
of microglia was observed in the non-injected and AAV8 injected brains (Supplementary Fig. 3).
Production of AAV8 biosensors. An AAV8 producer plasmid was created containing a Gateway® accepter 
site (Invitrogen). The Gateway® sequence was cloned into the backbone and was placed upstream of a minimal 
promoter driving a codon-optimised luciferase transgene and an enhanced GFP linked by a bicistronic linker, 
T2A (Supplementary Fig. 4). We have now assembled an extensive library of transcription factor binding ele-
ments in pENTR shuttle plasmids and these are shown in Supplementary Fig. 4. We selected the NFκB response 
element and an SFFV viral promoter for the insertion into the AAV gateway backbone. These two were chosen as 
they have been validated by both in vitro and in vivo means in our lentiviral system3.
AAV8 biosensor vectors were generated using the AAV8-SFFV-Luc-T2A-eGFP and AAV8- NFκB 
-Luc-T2A-eGFP backbones.
Neonatal administration of AAV8 biosensors. Having observed widespread transgene expres-
sion after a single neonatal administration of an AAV8-CMV-GFP vector, we chose to investigate the NFκB 
signalling expression profile by neonatal injection of the AAV8-NFκB-Luc-2A-GFP biosensor. We selected 
AAV8-SFFV-Luc-2A-GFP as a constitutively expressed control and to allow comparison with previous exper-
iments using lentivirus vectors3.
At P1 of development, mice received a 30 µl intravenous (IV) administration of AAV8 SFFV or AAV8 NFκB 
biosensor (1 × 1013 vg/ml). Mice underwent whole-body bioluminescence imaging over the course of develop-
ment to quantify luciferase expression.
Following IV injection of the AAV8 NFκB biosensor, luciferase expression was strongest in the spine, thorax, 
paws, lower abdominal and the mouth (Fig. 2A). In contrast, IV injection of the AAV8 SFFV biosensor resulted 
in whole-body luciferase expression but with strongest expression in the lower abdomen (Fig. 2A). The luciferase 
expression was quantified and showed stable transgene expression over development (Fig. 2B,C).
Additionally, to restrict the expression profile within the CNS and PNS, intracranial (IC) injections were also 
performed with AAV8 SFFV and AAV8 NFκB biosensors. P1 pups received 5 µl (1 × 1013 vg/ml) of either bio-
sensor, and whole-body bioluminescence imaging was undertaken over the course of development. Luciferase 
expression from the IC injected AAV8 NFκB biosensors was similar to that seen in the IV injected mice, predom-
inantly in the spine, thorax, paws, mouth, eyes and tail (Supplementary Fig. 6A).
A month after IC or IV injection of AAV8 SFFV or NFκB biosensor, the mice were harvested, immuno-
histochemistry and immunofluorescence with neuronal and astrocytic markers were performed to detect GFP 
expression in the brain. After IC injection of AAV8 SFFV, GFP expression was predominantly neuronal within 
the dentate gyrus and CA1 and CA3 regions of the hippocampus (Supplementary Figs. 7A and 8A), with some 
astrocytic cell targeting (Supplementary Fig. 8B). Both neuronal and astrocytic cells were transduced by IC AAV8 
NFκB and IV AAV8 SFFV (Supplementary Fig. 8A,B). However, following IV AAV8 SFFV, a mixture of cells were 
found to be positive for GFP within the hippocampal region after immunoperoxidase staining (Supplementary 
Fig. 7B). After co-staining these sections with neuronal and astrocytic markers, we found no co-localisation with 
GFP (Supplementary Fig. 8A,B).
Further to this, on a separate cohort of intravenously injected mice, we were able to show extensive whole-body 
bioluminescence at 240 days of development (Fig. 3).
Validation of the AAV8 NFκB biosensor. To assess whether the AAV8 NFκB could be exploited to 
report on NFκB signalling in pathological states, mice received ultra-pure lipopolysaccharide (LPS) which only 
acts through toll-like receptor 4 to induce translocation of NFκB from the cytosol to the nucleus13. At day 132 
after AAV administration, a single dose of LPS was administered intraperitoneally to both IV and IC injected 
groups. Bioimaging was taken at 4, 24, 48, 72 and 96 hours before (to correct for any perturbance in the signal 
caused by multiple imaging) and after LPS administration. A single administration of LPS resulted in a signifi-
cant increase in luciferase expression in IV (Fig. 4; p < 0.0001, n = 7) and IC AAV8 NFκB mice (Supplementary 
Fig. 9; p = 0.006, n = 7). The luciferase expression for individual mice which received IV injections is shown in 
Supplementary Fig. 10.
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Discussion
In this study, we have shown for the first time that light-producing somatic-transgenic rodents can be produced 
by a single neonatal administration of an AAV8 biosensor. Specifically, we have demonstrated that AAV8 vectors 
cross the blood brain barrier (BBB) and mediate systemic transgene expression after a single neonatal intravenous 
or intracranial administration.
Our results showed a systemic spread of transgene expression by a neonatal intravenous administration of a 
self-complementary AAV8 vector. This data agrees with previous work conducted by Nakai et al. which demon-
strated that AAV8 vectors cross the BBB and result in transduction of both neuronal and glial cells in the brain, 
albeit with a low efficiency14. These authors also presented transduction of cells within the liver, skeletal muscle, 
smooth muscle, cardiac muscle and pancreas14. However, we were able to show a much more extensive spread of 
transgene expression within the CNS and visceral organs such as the kidney and myenteric plexus. The strong 
and widespread GFP expression observed in our study maybe due to a number of factors including the use of a 
different promoter and route of administration.
Our analysis also demonstrated an improved safety profile within the CNS after a neonatal intravenous 
administration. It has been reported that lentiviral vector mediated expression of GFP elicits toxicity in Purkinje 
cells of the developing mouse cerebellum. This toxicity was attributed mainly to GFP overexpression although the 
authors could not discount the lentiviral vectors per se, or genotoxicity caused by vector integration in neuronal 
DNA as aggregating factors15. In contrast, we detected no microglial activation in the CNS suggesting that inflam-
mation or gliosis caused by the injection, the presence of vector, or expression of both luciferase and GFP did not 
occur. This suggests that the AAV system we describe may be preferable to our previously described lentiviral 
vector system2.
We performed neonatal intracranial injections of our AAV8 biosensors to monitor whether we could restrict 
the expression profile to the CNS and PNS. However, our results revealed that the intracranial injected mice 
showed a similar expression profile to the mice which received an intravenous administration. Previous work 
has shown that after a single adult intravenous injections of AAV8, transgene expression was observed within the 
CNS and also within the cervical, thoracic, and lumbar spinal cord sections. However, the expression profile was 
not significant compared to other serotypes such as AAVrh.816.
Figure 2. Whole-body bioluminescence imaging of mice which have received an intravenous administration 
of AAV8 SFFV or AAV8 NFκB vectors. New-born mice received intravenous injections of either AAV8 SFFV 
or AAV8 NFκB biosensors (n = 6 per group). We observed expression profiles from the two different AAV8 
biosensors (A), the same mouse was imaged on its front and back. Luciferase expression was quantified by 
whole-body bioluminescence imaging for a month (B,C), (mean +/− SD).
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In order to overcome this wide distribution profile, future experiments would involve the assessment of addi-
tional AAV capsids. These would include AAV-PHP.B, which is a new variant AAV capsid that transduces the 
CNS 40-fold greater than AAV9 after a single adult intravenous administration and targets astrocytes and neu-
rons17. Furthermore, AAV-PHP.eB an enhanced variant of AAV-PHP.B, efficiently transduces the CNS and PNS 
Figure 3. Whole-body bioluminescence imaging of mice which have received an intravenous administration 
of AAV8 NFκB or AAV8 SFFV vectors up to 240 days of development. New born mice received intravenous 
injections of AAV8 NFκB or AAV8 SFFV preformed biosensors (n = 8 per group). (A) the same mouse was 
imaged on its front and back. Luciferase expression was quantified by whole-body bioluminescence imaging for 
8 months (B), (mean +/− SD).
Figure 4. Up-regulation of luciferase signal mediated by a single dose of LPS. Bioluminescence imaging 
persisted more than 4 months during development in mice which received intravenous administration of the 
AAV8 NFκB biosensor (n = 7). At day 132 of development all the mice received a single dose of LPS which 
resulted in a significant up-regulation in luciferase expression in the IV injected mice, p < 0.0001.
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greater than the AAV-PHP.B and predominately targets neurons18. Adult injections would further restrict the 
transgene expression in the CNS. Kostoula et al. demonstrated CNS specific luciferase expression after adult 
stereotactic injections of AAV8-GFAP-luciferase into the hippocampus19. Therefore, in order to achieve CNS 
restricted and cell specific transduction profiles different configurations of AAV capsids and adult injections 
would have to be used.
We have established a unique technology which allows the production of somatic-transgenic light-emitting 
rodents. We have synthesised a library of >20 response elements, >10 promoters, most of which we have vali-
dated in the context of a lentiviral backbone in vitro, and several of them in vivo. To exploit the advantages of AAV, 
we gene synthesised an AAV backbone containing a Gateway acceptor site, and strategically placed multi-cloning 
sites with unique restriction sites to permit easy cloning.
As proof-of principle we inserted the NFκB response element, consisting of octuplet cognate binding ele-
ments, into the AAV backbone. A potential concern with introducing such sequences into the viral backbone 
is the loss of tandem repeats following propagation and amplification in bacteria20. However, sequencing of 
large-scale DNA preparations of this backbone confirmed that the repeats remained intact.
Here we demonstrate that administration of AAV biosensors by a single neonatal intravenous administration 
resulted in widespread luciferase expression, in comparison to our lentiviral biosensors which only transduced 
the liver3. The bio-distribution of luciferase expression differed between the constitutive AAV8 SFFV biosensor 
and the NFκB biosensor. A previous study demonstrated NFκB biosensor activity following administration of 
AAV by pancreatic infusion in adult mice21. Baseline expression rose rapidly in those mice but fell to modest lev-
els by 1 month. This may be attributable to an anti-luciferase or anti-capsid cytotoxic T-cell response eliminating 
transduced cells. In contrast, we observed stable expression for at least five months; it has been shown that neona-
tal gene transfer administration results in immune tolerization to the transgenic protein when using retrovirus22, 
AAV23 and adenovirus24 vectors.
We also conducted additional studies to test another AAV8 biosensor in vivo. We administered an AAV8 
biosensor containing a hypoxic response element (HRE), driving luciferase via tail vein injections to adult mice 
(8 weeks). At day 77 post injection, the mice were subjected to brief hypoxia (10% oxygen)25. A burst of biolumi-
nescence imaging was taken pre- and post-hypoxia and the results revealed no difference in luciferase expression 
after hypoxia (Supplementary Fig. 11). Therefore, highlighting that certain AAV biosensors aren’t as sensitive as 
germline transgenic mice in detecting subtle changes in cellular signalling.
Here we present for the first time the generation of somatic-transgenic mice with the use of AAV viral vectors 
delivered to neonatal mice. We have also shown widespread transgene expression after a single intracranial or 
intravenous neonatal administration of the AAV biosensors. We have validated the AAV biosensors with the use 
of agonists. This technology not only complements existing germline transgenic rodents but also maximises the 
use and reduces the numbers of animals used in biomedical research26. We have generated a non-invasive gene 
marking technology, which can be applied to systemic disease models. With the use of Gateway® cloning the 
assessment of different response elements can easily be achieved.
Methods and Materials
All methods were performed in accordance with the relevant guidelines and regulations.
Generation of the AAV biosensor plasmids. The AAV8-Gateway®-Luc-T2A-eGFP was synthesised by 
Aldevron (Aldevron, North Dakota, USA). This AAV plasmid consisted of a Gateway® sequence, placed upstream 
of a codon-optimised luciferase transgene, linked to an enhanced GFP by a bicistronic linker, T2A. The response 
element NFκB and constitutive promoter SFFV was cloned into an pENT plasmid3. By using the Gateway® clon-
ing kit (Invitrogen, Manchester, UK) and using the manufactures guidelines, the response element NFκB, HRE 
and constitutive promoter SFFV were individually inserted into the AAV backbone to generate the following 
plasmids; pAAV8-SFFV-Luc-T2A-eGFP, pAAV8-NFκB-Luc-T2A-eGFP and pAAV8-HRE-Luc-T2A-eGFP.
Recombinant AAV production. Recombinant AAV was produced, purified and titered using standard pro-
cedures. Briefly, HEK293T cells were double transfected with the pAAV8-SFFV-Luc-2A-eGFP or pAAV8-NFκB 
-Luc-2A-eGFP or pAAV8-HRE-Luc-T2A-eGFP plasmid, and the pDG8 plasmid expressing AAV2 Rep, AAV8 
Cap gene and adenovirus 5 helper functions (Plasmid Factory, Bielefeld, Germany) using polyethylenimine 
(PEImax, Polysciences Inc). After 72 hours of incubation at 37 °C, the cells were harvested by centrifugation and 
then lysed by freeze-thawing in lysis buffer. In parallel, the virus-containing supernatant was harvested and pre-
cipitated by using ammonium sulphate salt. Cell lysate and precipitated supernatant were treated with benzonase, 
clarified by centrifugation and filtered at 0.22 µm before purification.
The recombinant AAV virus preparations were purified by iodixanol step gradient: the viral preparation was 
overlaid with increasing concentrations of iodixanol (15%, 25%, 40% and 60%, OptiPrep; Sigma-Aldrich, Dorset, 
UK). The tubes were centrifuged at 40,000 rpm for 3 hours at 18 °C in a Sorvall Discovery 90SE ultracentrifuge 
using a TH641 rotor (Thermo Scientific, Paisley, UK). The vector was extracted from the 40% fraction with a 
19-gauge needle. Purified vector fractions were dialysed against PBS overnight.
Real-time PCR and alkaline gel electrophoresis were used to assess the viral genome titers and integrity of the 
viral genome27,28, the capsid titers were determined by SDS PAGE electrophoresis29.
AAV8 containing the enhanced GFP gene driven by the cytomegalovirus promoter (AAV8-CMV-eGFP) in 
a self-complementary configuration was obtained from the UPenn Vector Core facility (Philadelphia, USA) at a 
titre of 1 × 1013 vg/ml.
Animal procedures. Outbred CD1 mice and MF1 mice used in this study were supplied by Charles Rivers 
Laboratories. All procedures were performed under United Kingdom Home Office Project License 70/8030, 
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approved by the ethical review committee and followed institutional guidelines at University College London. All 
methods were performed in accordance with the relevant guidelines and regulations.
neonatal intracranial and intravenous injections. For intracranial injections, mice (random mix of 
males and females) were subjected to brief hypothermic anaesthesia on the day of birth, followed by unilateral 
injections of concentrated AAV vector (5 µl in total; 1 × 1013 vector genomes/ml) into the cerebral lateral ventri-
cles using a 33 gauge Hamilton needle (Fisher Scientific, Loughborough, UK), following co-ordinates provided 
by Kim et al.30. For intravenous injections, pups were subjected to brief hypothermic anaesthesia followed by 
intravenous injections of AAV vectors into the superficial temporal vein31, with a total volume of 25 µl (1 × 1013 
vg/ml). The neonates were then allowed to return to normal temperature before placing them back with the dam.
Adult tail vein injections. Adult male CD1 mice were placed in an chamber set at 37 °C, after which they 
were anaesthetised with isoflurane with 21% oxygen (Abbotts Laboratories, London, UK). A total volume of 
100 µl (1 × 1010 vg/ml) of AAV8-HRE-Luc-T2A-eGFP was administered via tail vein to each mouse. The mice 
were then placed back into their cages.
Whole-body bioluminescence imaging. Where appropriate, mice were anaesthetised with isoflurane 
with 21% oxygen. D-luciferin (Gold Biotechnologies, ST Louis, USA) was administered by intraperitoneal 
injection at a concentration of 15 mg/mL. Mice were imaged 5 minutes after luciferin injection using a cooled 
charged-coupled device camera, (IVIS Lumina II, Perkin Elmer, Coventry, UK) for between 1 second and 5 min-
utes. Photon output of the whole-body was measured using Living Image Software (Perkin Elmer) and light 
output quantified and expressed as photons per second per centimetre squared per steradian (photons/second/
cm2/sr).
Hypoxia. Adult mice (19 week old mice) were placed inside a hypoxic chamber which was air tight. The mice 
were subjected to 10% oxygen mixed with nitrogen for 2 hours following protocols mentioned in Karda et al.2 and 
Nakada et al.25. The mice were then returned to their dams.
collection of brain tissues. Mice were anaesthetised at day 35 of development using Isoflurane and the 
right cardiac atrium was incised, followed by injection of heparinized PBS into the left cardiac ventricle. The 
brains were removed and fixed in 4% paraformaldehyde (PFA) and then cryoprotected in 30% sucrose in 50 mM 
PBS. Brains were sectioned using a sliding microtome (Carl Zeiss, Welwyn Garden City, UK) to generate 40 µm 
transverse sections31. Sections were stored in 30% sucrose in TBS, ethylene glycol and 10% sodium azide.
immunoperoxidase immunohistochemistry. To visualise CD68 and GFP immunoreactivity, sections 
were treated with 30% H2O2 in TBS for 30 minutes. They were blocked with 15% rabbit serum for CD68 (Vector 
Laboratories, Cambridge, UK) and goat serum for GFP (Vector Laboratories) in Tris buffered saline and Tween 
20 (TBST) for 30 minutes. This was followed by the addition of primary antibody, rat anti-mouse CD68 (1:100; 
Biorad, Hertfordshire, UK), mouse anti-GFP (1:10,000; Abcam, Cambridge, UK) in 10% serum and TBST and 
incubated over night at 4 °C with constant gentle aggitation. The following day the sections were treated with 
the secondary rat anti-rabbit antibody for CD68 (1:1000; Vector Laboratories) and goat anti-rabbit (1:1000 dilu-
tion; Vector Laboratories) in 10% rat or goat serum in TBST for 2 hours. The sections were incubated for a fur-
ther 2 hours with Vectastain ABC (Vector Laboratories). 0.05% of 3,3′-diaminobenzidine (DAB) was added and 
left for a couple of minutes. Sections were transferred to ice cold TBS. Individual brain sections were mounted 
onto chrome gelatine-coated Superfrost-plus slides (VWR, Poole, UK) and left to dry for 24 hours. The slides 
were dehydrated in 100% ethanol and placed in Histoclear (National Diagnostics, Yorkshire, UK) for 5 min-
utes before adding a coverslip with DPX mounting medium (VWR). DAB stained sections in Supplementary 
Figs. 1 and 2 were viewed using an Axioskop 2 Mot microscope (Carl Zeiss Ltd.) and representative images were 
captured using an Axiocam HR camera and Axiovision 4.2 software (Carl Zeiss Ltd.). DAB stained sections in 
Supplementary Fig. 7 were viewed using Leica MZ16F microscope software.
fluorescence immunohistochemistry. A similar protocol was followed as with the immunoperoxidase 
stain; however H2O2 treatment was omitted. Followed protocol mentioned in Karda et al.2.
Quantitative analysis of immunohistological staining. GFP and CD68 expression was quantified 
by thresholding analysis as previously described12,32. Briefly, 40 non-overlapping RGB images were taken from 
four consecutive sections through the somatosensory barrel field (S1BF), caudate putamen (Cpu), the Cornu 
Ammonis region 1 of the hippocampus, (CA1), piriform cortex (piriform cort), and the 10Cb region of the cer-
ebellum (10Cb). The images were captured using a live video camera (JVC, 3CCD, KY-F55B) mounted onto a 
Zeiss Axioplan microscope using the x40 objective lens. All camera and microscope calibration and settings 
were kept constant throughout the image capture period. Images were analysed for optimal segmentation and 
immunoreactive profiles were determined using Image-Pro Plus (Media Cybernetics). Foreground immunos-
taining was accurately defined according to averaging of the highest and lowest immunoreactivities within the 
sample population for a given immunohistochemical marker (per colour/filter channel selected) and measured 
on a scale from 0 (100% transmitted light) to 255 (0% transmitted light) for each pixel. This threshold setting was 
constant to all subsequent images analyzed for the antigen used. Immunoreactive profiles were discriminated in 
this manner to determine the specific immunoreactive area (the mean grey value obtained by subtracting the total 
mean grey value from non-immunoreacted value per defined field). Macros were recorded to transfer the data to 
a spreadsheet for subsequent statistical analysis.
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Statistics. The data from Supplementary Figs. 2 and 3 were plotted graphically as the mean percentage area 
of immune-reactivity per field ± S.D or S.E.M. for each region. Two-way ANOVA with and a Sidak’s multiple 
comparison was performed in Fig. 4 and Supplementary Fig. 9.
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Published: xx xx xxxx
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